Skip to main content
BIONIME logo

BIONIME — Investor Relations & Filings

Ticker · 4737 ISIN · TW0004737002 TW Manufacturing
Filings indexed 1,740 across all filing types
Latest filing 2022-02-10 Director's Dealing
Country TW Taiwan
Listing TW 4737

About BIONIME

www.bionime.com

Bionime Corporation is a biotechnology firm specializing in the research, design, and manufacturing of comprehensive blood glucose management systems. The company develops high-precision monitoring solutions for both personal home use and professional medical environments, including Blood Glucose Meters (BGM), Continuous Glucose Monitoring Systems (CGM), and Point-of-Care Testing (POCT). Under its proprietary brand, RIGHTEST, Bionime integrates medical, chemical, electronic, and precision machinery expertise to deliver products that rival international standards. A core component of its offering is a cloud-based management ecosystem powered by IoT digital solutions, which synchronizes medical data with patient care services. With over 480 core patents in CGM technology and a commitment to Industry 4.0 smart production, Bionime focuses on enhancing diabetes care through technical innovation and a human-centered approach to health monitoring.

Recent filings

Filing Released Lang Actions
111年01月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, supervisors, and senior management. It includes data on shares held at appointment, changes during the month, and current holdings, with specific mention of identities such as chairman, directors, supervisors, and financial department heads. The content is focused on insider share transactions and holdings rather than financial results, governance policies, or meeting materials. There is no indication of a report publication or announcement, nor is it a transcript or legal proceeding. The document is not a general regulatory filing or a report on remuneration or voting results. Given the detailed insider shareholding data, the document best fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length (11,899 characters) supports it being a substantive report rather than a brief announcement.
2022-02-10 Chinese
111年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabular disclosure of shareholdings and pledged shares by company insiders, including directors, supervisors, and senior management. It lists share counts, pledged shares, and related party holdings. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. This type of disclosure aligns with insider share transactions or holdings reporting. Given the nature of the data and the focus on directors and insiders' shareholdings, the document fits best under the category of Director's Dealing (DIRS). The document length is short and does not contain financial statements or meeting results, so it is not an annual or interim report or voting results. Therefore, the classification is DIRS with high confidence.
2022-02-10 Chinese
111年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (華廣) reporting on the status of fund loans and endorsement guarantees for the current and previous month, including cumulative amounts and limits. It contains no detailed financial statements or analysis, nor does it mention any report publication or certification. The content is a regulatory disclosure of financial status related to guarantees and loans, typical of a Regulatory Filing (RNS) category. The document length is short (601 characters), and it does not qualify as a full financial report or announcement of a report publication.
2022-02-09 Chinese
111年1月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a brief financial summary showing monthly and cumulative net operating revenue figures for a company named 華廣 for the period 民國111年01月 (January 2022). It includes percentage changes and explanations for revenue variations. The document is very short (794 characters) and contains only summarized financial data without detailed financial statements or analysis. It does not represent a full financial report like an Annual Report (10-K) or Interim Report (IR). It is more akin to a brief factsheet or summary of key financial figures. Therefore, the best fitting category is Fund Information / Factsheet (FS).
2022-02-09 Chinese
公告本公司法人董事改派代表人
Board/Management Information Classification · 100% confidence The document is a short announcement (736 characters) about a change in the company's board representative, specifically the appointment of a new representative for a corporate director. It includes details such as names, dates, and reasons for the change. There is no financial data, no report attached or referenced, and it concerns management changes. According to the definitions, this fits the category of Board/Management Information (MANG).
2022-01-28 Chinese
公告本公司法人董事代表人辭世
Board/Management Information Classification · 100% confidence The document is a formal announcement from a listed company (華廣) regarding the death of a corporate director representative (法人董事代表人辭世). It includes details about the deceased director, the date of the event, and notes that a new appointment will be announced later. There is no financial data, no report attached or referenced, and no indication of a meeting or voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-01-10 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.